Clinical Trials Browser

Carcinoma, Hepatocellular, Neoplasm Metastasis

NCT04138628 2026-03-02

TOMBOLA

Phase 2 Active not recruiting

154 enrolled

Genitourinary

Urinary Bladder Neoplasms, Neoplasm Metastasis

NCT05542407 2026-01-29

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Phase 1 Recruiting

58 enrolled

GynecologicOtherSarcoma

Carcinosarcoma, Disease, Neoplasm Metastasis, Obesity, Endometrial Neoplasms

NCT05276284 2026-01-14

TEMPLE

Phase 1/2 Completed

18 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT01898117 2025-11-26

Triple-B

Phase 2 Active not recruiting

304 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT03693014 2025-10-06

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

Phase 2 Active not recruiting

69 enrolled

GenitourinaryThoracic

Urinary Bladder Neoplasms, Kidney Neoplasms, Lung Neoplasms, Neoplasm Metastasis

NCT06416436 2025-06-29

Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients

Phase 1 Withdrawn

Tumor-Agnostic

Neoplasm Metastasis

NCT03108131 2025-05-28

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

Phase 2 Completed

49 enrolled 10 charts

Adenocarcinoma, Mucinous, Neoplasm Metastasis, Neoplasms

NCT04602078 2025-04-24

AUREA

Phase 2 Completed

82 enrolled 20 charts

Genitourinary

Carcinoma, Transitional Cell, Neoplasm Metastasis, Neoplasms

NCT03024437 2025-03-20

Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma

Phase 1/2 Terminated

31 enrolled 19 charts

Genitourinary

Kidney Neoplasms, Neoplasm Metastasis

NCT04551521 2025-01-08

CRAFT: The NCT-PMO-1602 Phase II Trial

Phase 2 Completed

72 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT05007613 2025-01-01

Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Phase 2 Completed

24 enrolled

Gastrointestinal

Carcinoma, Squamous Cell, Esophageal Neoplasms, Neoplasm Metastasis

NCT04817956 2024-02-29

IMPRESS-N

Phase 2 Recruiting

3,000 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT03698461 2024-01-31

CLIMB

Phase 2 Completed

20 enrolled

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT04639245 2023-08-03

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

Phase 1/2 Terminated

1 enrolled 6 charts

BreastGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03147040 2022-07-19

GELATO

Phase 2 Terminated

23 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

Clinical Trials

TRIPLET

TOMBOLA

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

TEMPLE

Triple-B

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

AUREA

Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma

CRAFT: The NCT-PMO-1602 Phase II Trial

Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

IMPRESS-N

CLIMB

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

GELATO